What is the treatment for pericarditis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Pericarditis

First-line treatment for pericarditis is a combination of aspirin or NSAIDs plus colchicine, with treatment duration guided by symptom resolution and normalization of CRP. 1

Acute Pericarditis Treatment Algorithm

First-Line Therapy

  • NSAIDs/Aspirin (Class I, Level A evidence) 1

    • Aspirin: 750-1000 mg every 8 hours for 1-2 weeks
    • Ibuprofen: 600 mg every 8 hours for 1-2 weeks
    • Indomethacin: 25-50 mg every 8 hours (for recurrent cases)
    • Provide gastroprotection with all NSAID therapy
    • Taper by decreasing doses gradually after symptom resolution and CRP normalization
  • Add Colchicine (Class I, Level A evidence) 1, 2

    • Weight-adjusted dosing:
      • <70 kg: 0.5 mg once daily
      • ≥70 kg: 0.5 mg twice daily
    • Duration: 3 months for first episode, 6 months for recurrent cases
    • Reduces recurrence rate from 37.5% to 16.7% (NNT = 4) 3

Second-Line Therapy

  • Low-dose corticosteroids (only if NSAIDs/colchicine contraindicated or failed, and infection excluded) 1
    • Prednisone 0.2-0.5 mg/kg/day (not 1.0 mg/kg/day)
    • Maintain until symptom resolution and CRP normalization, then taper slowly
    • Caution: Corticosteroids increase risk of recurrence and chronicity 1

For Refractory/Recurrent Cases

  • Triple therapy (NSAIDs + colchicine + low-dose corticosteroids)
  • For corticosteroid-dependent cases: Consider IL-1 blockers (anakinra) or immunosuppressants 3

Treatment Based on Etiology

Idiopathic/Viral Pericarditis (Most Common in Developed Countries)

  • Standard therapy as above
  • Good prognosis (<1% risk of constriction) 1, 4

Bacterial Pericarditis

  • Urgent pericardial drainage
  • Appropriate antibiotics based on culture results
  • Higher risk of constriction (20-30%) 1, 5

Tuberculous Pericarditis

  • Anti-tuberculosis therapy
  • Consider adding corticosteroids 5

Activity Restrictions

  • Non-athletes: Restrict physical activity until symptom resolution and normalization of CRP, ECG, and echocardiogram 1
  • Athletes: Restrict for at least 3 months and until normalization of all parameters 1

Monitoring and Follow-up

  • Use C-reactive protein (CRP) to guide treatment duration and assess response 1
  • Continue therapy until complete symptom resolution and CRP normalization
  • Monitor for recurrence (occurs in 15-30% of cases without colchicine) 1, 3

Important Considerations and Pitfalls

  • Avoid corticosteroids as first-line therapy - they increase risk of recurrence and chronicity 1
  • Proper tapering is essential - too rapid tapering of anti-inflammatory drugs can lead to recurrence
  • Colchicine reduces recurrence by >50% - should be added to all first-line regimens 2
  • Treatment duration should be symptom and CRP-guided - don't stop therapy prematurely
  • Recognize different types of pericarditis:
    • Acute: new-onset
    • Incessant: symptoms persisting >4-6 weeks
    • Chronic: lasting >3 months
    • Recurrent: symptom-free interval of ≥4-6 weeks followed by recurrence 1

Most patients with idiopathic/viral pericarditis have excellent long-term prognosis with appropriate treatment, with rare progression to tamponade (<3%) or constrictive pericarditis (<0.5%) 3, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A randomized trial of colchicine for acute pericarditis.

The New England journal of medicine, 2013

Research

Acute pericarditis: Update on diagnosis and management.

Clinical medicine (London, England), 2020

Research

Bacterial pericarditis: diagnosis and management.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.